title: A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
abstract: BACKGROUND
  Patients with human immunodeficiency virus (HIV) infection and latent tuberculosis are at substantial risk for the development of active tuberculosis. As a public health measure, prophylactic treatment with isoniazid has been suggested for HIV-infected persons who have anergy and are in groups with a high prevalence of tuberculosis.
  
  
  METHODS
  We conducted a multicenter, randomized, double-blind, placebo-controlled trial of six months of prophylactic isoniazid treatment in HIV-infected patients with anergy who have risk factors for tuberculosis infection. The primary end point was culture-confirmed tuberculosis.
  
  
  RESULTS
  The study was conducted from November 1991 through June 1996. Over 90 percent of the patients had two or more risk factors for tuberculosis infection, and nearly 75 percent of patients were from greater New York City. After a mean follow-up of 33 months, tuberculosis was diagnosed in only 6 of 257 patients in the placebo group and 3 of 260 patients in the isoniazid group (risk ratio, 0.48; 95 percent confidence interval, 0.12 to 1.91; P=0.30). There were no significant differences between the two groups with regard to death, death or the progression of HIV disease, or adverse events.
  
  
  CONCLUSIONS
  Even in HIV-infected patients with anergy and multiple risk factors for latent tuberculosis infection, the rate of development of active tuberculosis is low. This finding does not support the use of isoniazid prophylaxis in high-risk patients with HIV infection and anergy unless they have been exposed to active tuberculosis.
authors.affiliation: Medical Service, Veterans Affairs Medical Center, and Georgetown University, Washington, D.C. 20422, USA.
authors.forename: F M
authors.initials: FM
authors.lastname: Gordin
authors.forename: J P
authors.initials: JP
authors.lastname: Matts
authors.forename: C
authors.initials: C
authors.lastname: Miller
authors.forename: L S
authors.initials: LS
authors.lastname: Brown
authors.forename: R
authors.initials: R
authors.lastname: Hafner
authors.forename: S L
authors.initials: SL
authors.lastname: John
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: A
authors.initials: A
authors.lastname: Vaughn
authors.forename: C L
authors.initials: CL
authors.lastname: Besch
authors.forename: G
authors.initials: G
authors.lastname: Perez
authors.forename: S
authors.initials: S
authors.lastname: Szabo
authors.forename: W
authors.initials: W
authors.lastname: El-Sadr
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid